Related Experiment Video
Updated: Mar 24, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network
Pedro N Aguiar1, Ilka Lopes Santoro1, Hakaru Tadokoro1
1Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
Background:
Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer.
Methods:
We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines.
Results:
13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06).
Conclusion:
Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
